Claims

1. A stable antibody-containing liquid formulation, characterized by comprising arginine and methionine, wherein the immunoglobulin class of the antibody is IgG.

2. The formulation of claim 1 further comprising a histidine buffering agent.

3. The formulation of claim 1 or 2 further comprising a surfactant.

4. The formulation according to any of claims 1 to 3 containing the antibody in an amount of at least 50 mg/ml.

5. The formulation according to any of claims 1 to 3 containing the antibody in an amount of at least 100 mg/ml.

6. The formulation according to any of claims 1 to 3 containing the antibody in an amount of at least 120 mg/ml.

7. The formulation according to any of the preceding claims wherein the antibody is an anti-IL-6 receptor antibody.

8. A stable liquid formulation containing an anti-IL-6 receptor IgG antibody, characterized by comprising arginine and methionine.

9. The formulation according to any of the preceding claims wherein the antibody is a humanized antibody or human antibody.

10. The formulation according to any of the preceding claims further comprising tryptophan.

11. The formulation according to any of claims the preceding claims having the pH in the range from 4 to 8.

12. The formulation according to any of the preceding claims wherein the arginine is present in an amount of from 50 to 1500mM.

13. The formulation according to any of the preceding claims having a viscosity of from 2 to 15 mPa·s.

14. The formulation according to any of the preceding claims, which is stable at 22-28°C for at least 6 months.

15. The formulation according to any of claims 1 to 13, characterized in that dimerization of antibody molecules is inhibited.

16. The formulation according to any of claims 1 to 13, characterized in that deamidation of antibody molecules is inhibited.

17. The formulation according to any of claims 1 to 13, which is for subcutaneous administration.

18. The formulation according to any of claims 1 to 13 which has not been subjected to lyophillization during preparation of the formulation.

19. A method for inhibiting dimerization of molecules of an IgG antibody in a liquid formulation containing the IgG antibody, comprising adding arginine and methionine to the liquid formulation.